Description
The opportunity is for the supply of Lisinopril HCTZ tablets. The contract has been awarded to Exelan Pharmaceuticals Inc. The contract details include the exercise of Option 1, effective from February 1, 2024, to January 31, 2025. All other terms and conditions remain unchanged.
• The contract is for the supply of pharmaceuticals, specifically Lisinopril HCTZ tablets.
• The contract has been awarded to Exelan Pharmaceuticals Inc.
• The contract includes an option to extend the term, which has been exercised.
• The contract details include the exercise of Option 1, effective from February 1, 2024, to January 31, 2025.